By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

NeuroDerm Ltd. 



Ofakim      Israel
Phone: 925-270-0519 Fax: 925-290-1209


SEARCH JOBS


Industry
Pharmaceutical






Company News
NeuroDerm Ltd. Announces Presentation Of ND0612L Top-Line Phase 2 Results And ND0612H Preliminary Interim Phase 2a Results At The 2014 Parkinson's Disease Therapeutics Conference 10/23/2014 7:26:35 AM
Israeli Biotech NeuroDerm Ltd. Files For $65 Million IPO 9/16/2014 6:56:34 AM
NeuroDerm Ltd. Banks $16 Million 8/21/2014 3:48:34 PM
NeuroDerm Ltd. Announces Eligibility For European Union Centralized Procedure For ND0612H, A Novel Treatment For Advanced Parkinson's Disease 8/4/2014 7:15:05 AM
NeuroDerm Ltd. Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6/19/2013 10:34:35 AM
NeuroDerm Ltd. Announces Presentation of ND0612 Phase 1 and Phase 2 Results at the 2013 International Congress of Parkinson's Disease and Movement Disorders 6/13/2013 6:37:07 AM
NeuroDerm Ltd. Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of ND0612 for Parkinson's Disease 6/3/2013 10:54:32 AM
NeuroDerm Ltd. to Present at the Jefferies and Co. 2013 Global Healthcare Conference in New York City 5/31/2013 9:40:20 AM
NeuroDerm Ltd. Announces Enrollment in a Phase 2 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinson's Disease 4/15/2013 10:10:03 AM
NeuroDerm Ltd. Announces Positive Results of a Phase I Study of ND0612 for the Treatment of Parkinson's Disease 3/4/2013 9:43:19 AM
12
//-->